TB commonly refers to tuberculosis, an infectious disease caused by Mycobacterium tuberculosis, usually affecting the lungs but potentially involving many organs. It remains one of the leading infectious causes of death globally.
Three advances in TB diagnostics: a portable $300 device delivering results in 30 minutes, a Quick DNA kit detecting drug resistance in 5 minutes, and an ultrasensitive test finding TB DNA in 12-16% of hospitalized US patients.
A vaccine and two novel tuberculosis treatments are advancing through Phase III trials, marking renewed momentum in TB research. Tuberculosis claims over 1.25 million lives annually with 10.6 million new cases in 2023, while current treatments face challenges of high pill burden, toxicity, and rising resistance.
The World Health Organization has recommended new portable TB diagnostic tests that deliver results in under an hour, while researchers developed an inhalable nanoparticle treatment that could replace daily pills. TB remains the world's deadliest infectious disease, killing 1.2 million people in 2024 despite being preventable and curable.
Researchers have developed an inhalable nanoparticle system for delivering rifampin directly to the lungs, potentially reducing tuberculosis treatment from daily to once-weekly dosing while lowering side effects and improving drug effectiveness.
BioVersys has dosed the first patient in a Phase 2b trial evaluating alpibectir-ethionamide (AlpE) in combination with first-line TB drugs, following promising Phase 2a results published in the New England Journal of Medicine.
Researchers have created a nasal vaccine platform that protects mice against flu, COVID-19, SARS, and bacterial infections by activating both innate and adaptive immune systems, offering a fundamentally different approach to disease prevention.
Zimbabwe began rolling out lenacapavir, a twice-yearly injectable HIV prevention drug, on February 19 in Epworth. The program will initially target more than 46,000 people at high risk across 24 sites nationwide.
Vir Biotechnology is set to report Q4 2025 earnings on Feb 23, 2026, with analysts expecting revenue of $19.91-$23.18 million and a loss of $0.41-$0.50 per share, marking a 61% year-over-year revenue increase.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07164742 |
Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure) |
RECRUITING | NA |
| NCT06701110 |
Pharmacokinetic Study of Sudapyridine（WX-081）in Healthy Chinese Subjects |
RECRUITING | PHASE1 |
| NCT05405296 |
Evaluation of the Truenat™MTB Plus/COVID-19 Test for TB (Tuberculosis) and COVID-19 (SARS-CoV2) |
ACTIVE_NOT_RECRUITING | |
| NCT04673227 |
Cytometric Immunodiagnostics of Latent Tuberculosis Infection (LTBI) |
UNKNOWN | |
| NCT04645836 |
Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'. |
COMPLETED | NA |
| NCT04298905 |
Leveraging mHealth to Enable and Adapt CHW Strategies to Improve TB/HIV Patient Outcomes in SA |
ACTIVE_NOT_RECRUITING | NA |
| NCT03208725 |
Childhood Acute Illness and Nutrition Network |
UNKNOWN | |
| NCT01055145 |
Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients |
TERMINATED | PHASE3 |
| NCT00654316 |
Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine |
COMPLETED | PHASE1 |
| NCT00480714 |
A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers |
COMPLETED | NA |
